Immunohistochemical Biomarkers in Ductal Carcinoma <i>In Situ</i>  

作　　者：I. Petrone F. Resende Rodrigues P. Valverde Fernandes E. Abdelhay I. Petrone;F. Resende Rodrigues;P. Valverde Fernandes;E. Abdelhay(Stem Cell Laboratory, Center for Bone Marrow Transplants, Brazilian National Cancer Institute—INCA, Rio de Janeiro, Brazil;Division of Pathology, Brazilian National Cancer Institute—INCA, Rio de Janeiro, Brazil)

机构地区：[1]Stem Cell Laboratory, Center for Bone Marrow Transplants, Brazilian National Cancer Institute—INCA, Rio de Janeiro, Brazil [2]Division of Pathology, Brazilian National Cancer Institute—INCA, Rio de Janeiro, Brazil

出　　处：《Open Journal of Pathology》2020年第4期129-146,共18页病理学期刊（英文）

摘　　要：<div style="text-align:justify;"> <span style="font-family:Verdana;"><strong>Introduction:</strong> Breast ductal carcinoma <span style="white-space:nowrap;"><i>In Situ</i></span> (DCIS) can be defined as a malignant epithelial proliferation with growth limited by the basal membrane of the ductal epithelium, with no evidence of stromal invasion. There has been a trend of trying to subcategorize DCIS based on cell proliferation assays (Ki67) and the expression of hormone receptors and the human epidermal growth receptor (HER-2) as detected by immunohistochemistry, similar to invasive breast carcinomas (IBC). The aims were to evaluate the expression of breast cancer marker proteins in DCIS by immunohistochemistry to better categorize it. <strong>Methods:</strong> 46 biopsies from women with DCIS and IBC Luminal A-like were evaluated by immunohistochemistry staining of proteins already known to be biomarkers in IBC. For controls, normal breast tissue from mammoplasty (n = 3) was used. <strong>Results:</strong> Our results showed an increase of estrogen receptor (ER) and progesterone receptor (PR) expression relative to that in normal tissue samples (p < 0.0001). No differences in steroid hormone expression patterns were seen between DCIS and IBC tumors (p = 0.3145;p = 0.7341, respectively). The proliferation levels of the DCIS and IBC samples were similar as evaluated by the Ki67 labeling index. Only 12.90% of samples showed amplification of HER-2. <strong>Conclusion:</strong> The biology of DCIS is not well understood given the complexity and heterogeneity of the disease, which makes it important to better sub-categorize this tumor, especially considering the possibility of identifying DCIS cases with the potential for recurrence and evolution into IBC.</span> </div><div style="text-align:justify;"> <span style="font-family:Verdana;"><strong>Introduction:</strong> Breast ductal carcinoma <span style="white-space:nowrap;"><i>In Situ</i></span> (DCIS) can be defined as a malignant epithelial proliferation with growth limited by the basal membrane of the ductal epithelium, with no evidence of stromal invasion. There has been a trend of trying to subcategorize DCIS based on cell proliferation assays (Ki67) and the expression of hormone receptors and the human epidermal growth receptor (HER-2) as detected by immunohistochemistry, similar to invasive breast carcinomas (IBC). The aims were to evaluate the expression of breast cancer marker proteins in DCIS by immunohistochemistry to better categorize it. <strong>Methods:</strong> 46 biopsies from women with DCIS and IBC Luminal A-like were evaluated by immunohistochemistry staining of proteins already known to be biomarkers in IBC. For controls, normal breast tissue from mammoplasty (n = 3) was used. <strong>Results:</strong> Our results showed an increase of estrogen receptor (ER) and progesterone receptor (PR) expression relative to that in normal tissue samples (p < 0.0001). No differences in steroid hormone expression patterns were seen between DCIS and IBC tumors (p = 0.3145;p = 0.7341, respectively). The proliferation levels of the DCIS and IBC samples were similar as evaluated by the Ki67 labeling index. Only 12.90% of samples showed amplification of HER-2. <strong>Conclusion:</strong> The biology of DCIS is not well understood given the complexity and heterogeneity of the disease, which makes it important to better sub-categorize this tumor, especially considering the possibility of identifying DCIS cases with the potential for recurrence and evolution into IBC.</span> </div>

关 键 词：Breast Cancer Ductal Carcinoma In Situ IMMUNOHISTOCHEMISTRY Biomarker Proteins CATEGORIZATION 

分 类 号：R73[医药卫生—肿瘤]